Pembrolizumab Treatment-Induced Liver Toxicity.

Autor: Calderon B; Institut Sainte Catherine, Avignon, France., Stancu A; Institut Sainte Catherine, Avignon, France., Vanel FR; Institut Sainte Catherine, Avignon, France., Vazquez L; Institut Sainte Catherine, Avignon, France.
Jazyk: angličtina
Zdroj: Case reports in gastroenterology [Case Rep Gastroenterol] 2021 Aug 11; Vol. 15 (2), pp. 742-750. Date of Electronic Publication: 2021 Aug 11 (Print Publication: 2021).
DOI: 10.1159/000518128
Abstrakt: T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3-4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.
Competing Interests: The authors have no conflict of interest to declare.
(Copyright © 2021 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje